AP-1, c/EBP and NFκB were required but not sufficient to drive the stress-induced increase in IL-8
ADPKD liver cysts occur in 94% of 35-46 year old ADPKD subjects (6) , can grow to over five times the size of a normal liver (42) and account for up to 10% of ADPKD morbidity and mortality. The clinical complications from the liver cysts arise from the compression of adjacent tissues, organs and vessels by the enlarged livers. Inhibition of cyst growth is predicted to ameliorate the clinical presentation of ADPKD liver cyst disease.
While cystogenesis is clearly linked to the PKD1 or PKD2 mutations, the growth of liver cysts is impacted by extragenetic factors (39) . It is hypothesized that autocrine/paracrine signaling by factors secreted by the cyst lining epithelial cells controls the growth rate of kidney and liver cysts. A number of studies have implicated or demonstrated the presence of cytokines and growth factors in kidney cyst fluids . Likewise, cytokine array analysis documented the presence of a number of specific cytokines and growth factors within human liver cyst fluid. The present study directly compared and contrasted the cytokine/growth factor profiles in liver and kidney cyst fluids and found the profiles were markedly different. Among the factors that were specifically elevated within human liver cyst fluids were agonists for CXCR2 receptors, including IL-8, ENA78 and GROα. CXCR2 agonists were of specific interest since they cannot only attract inflammatory cells into diseased tissues (28) but can also promote angiogenesis in the absence of preceding inflammation (1) and induce proliferation of epithelial cells (44) .
Angiogenesis and proliferation of the cyst-lining epithelial cells are considered essential elements for cyst growth. Consequently, the present studies evaluated the potential for CXCR2 agonists within liver cyst fluid to directly promote the proliferation of both endothelial and epithelial cells.
Finally, the expression of cytokines and growth factors, including IL-8, is generally low under basal conditions and increased in response to specific stresses experienced by cells. Hypoxia and cell stretching are two stressors that are likely to be imposed onto the liver cyst epithelial cells. The lining epithelial cells in human ADPKD liver cyst wall display morphologic features of ischemia (10, 30) and ischemia induces the expression of a number of cytokines and growth factors, including IL-8 (36) . In vivo human studies show ADPKD liver cyst-lining epithelial cells retain a strong, regulated secretory capacity that increases intralumenal cyst pressure and, by inference, increase cell stretching (12). In pulmonary epithelial cells, cell stretching induced an increase in IL-8 (41) . Further, secretion-induced stretching of epithelial cysts in three dimensional matrices increased the rate of cell proliferation (38) . Consequently, the impact of hypoxia and cell stretching on IL-8 expression was evaluated. In total, the present in vitro studies demostrate the potential for CXCR2 agonists to contribute to the in vivo growth of ADPKD liver cysts and highlights the CXCR2 signaling pathway as a potential therapeutic target for the treatment of ADPKD liver cyst disease.
MATERIALS AND METHODS

Reagents.
Unless otherwise noted, all cell culture media and reagents were purchased from Gibco-Invitrogen (Grand Island, NY). Fetal Bovine Serum (FBS) was purchased from Hyclone-QB Perbio (Logan, UT). All tissue culture plastic materials were purchased from Beckton Dickinson (Lincoln Park, NJ). Mouse monoclonal anti-PCNA antibody was purchased from BD-Pharmingen (San Jose, CA) and anti-human actin was from Sigma Chemicals (St. Louis, MO). SB225002 (CXCR2 inhibitor) was purchased from Calbiochem (La Jolla, CA).
ADPKD liver and kidney cyst fluids.
The collection of all fluids and tissues from human patients was done in accordance with a protocol reviewed and approved by the Colorado Multiple Institution Review Board. All patients were fully informed and consented to participate in these studies.
Fluids from liver and kidney cysts were obtained by laparoscopic fenestration procedures and needle aspiration. Fluids from 7 to 20 individual cysts per liver were collected from 10 patients; fluids from 3 to 18 individual cysts per kidney were collected from 11 patients. In some cases cyst fluids from the same patient were pooled. All cyst fluid samples were stored at -80 o C until assayed. Removal of information that would permit identification of the donor of the cyst fluid samples has disallowed the demographic data on the liver and kidney cyst fluids to be compared and contrasted.
Pkd2(WS25/-) mice. C57BL/6 pkd2(WS25/-) mice were developed by Stefan Somlo (Yale University) and pkd2(+/-) and pkd2(WS25/+) breeding pairs were provided for this project. Pkd2(WS25/-) mice closely model the human condition by having one copy of pkd2 knocked out and having a second, recombinant-sensitive allele (i.e. WS25) that undergoes high rates of recombination to yield knock outs of the second copy of the gene in somatic cells during the life span of the animals. By four months of age, all pkd2(WS25/-) mice develop discernible kidney and liver cysts (45) . Over the subsequent four to eight months, these cysts grow and emerge from the tissues. Mice were genotyped by Southern blotting as previously reported (4).
Cell culture protocols.
Three different cell culture models were employed in these studies.
Primary cultures of pkd2(WS25/-) mouse liver cyst epithelial cells were used to evaluate the polarity of cytokine release. HMEC-1 cells, a human microvascular endothelial cell line (2) , were used to model the proliferative responses of liver cyst wall endothelial cells. Mz-ChA1 cells, a human cholangiocarcinoma cell line, were used to model the 'cystic' cholangiocytes that line the liver cyst wall.
pkd2(WS25/-) liver cyst epithelial cells.
Liver cyst epithelial cells were isolated from pkd2(WS25/-) mice as previously described (11). Briefly, liver cyst wall tissue was finely minced, suspended in Growth Media (DMEM-F12; 5% fetal bovine serum (FBS; Hyclone; Logan, UT), 2 mM glutamine, 1% non-essential amino acids, 1% lipid concentrate, 1% vitamin solution, 393 ng/ml dexamethasone (Sigma; St. Louis, MO), 25 ng/ml epidermal growth factor (Upstate Biologics, Lake
Placid, NY), 30 µg/ml bovine pituitary extract (Upstate Biologics, Lake Placid, NY), 3.4 µg/ml triiodothyrodine, 1% insulin-transferrin-Se, 0.4 µg/ml forskolin (Sigma; St. Louis, MO), 50 µg/ml soybean trypsin inhibitor; pH 7.5), placed above a 2 mm slab of rat tail collagen and the epithelial cells allowed to grow out onto the slab. Cells were passaged by digesting the collagen slab (1 mg/ml collagenase (Sigma; St. Louis, MO), 2 mg/ml dispase; 60 min at 37 o C), disrupting the monolayer into small epithelial 'islands' and reseeding with these 'islands' onto fresh collage slabs. Cells were maintained at 37 0 C under a humidified atmosphere with 5% CO 2.
HMEC-1 cells.
Human HMEC-1 cells (a kind gift from Dr. Sean Colgan, UCDHSC) were cultured in MCDB-131 (Invitrogen) supplemented with 10% FBS, L-glutamine, 10ng/ml epidermal growth factor (EGF; Upstate Biotechnology; Lake Placid, NY), and 1ug/ml hydrocortisone (Sigma; St. Louis, MO). Cells were harvested with 0.25 % trypsin-EDTA and passaged once a week. Cells were maintained at 37 0 C under a humidified atmosphere with 5% CO 2.
Mz-ChA1 cells.
Human Mz-ChA1 cells were cultured in CMRL Medium-1066 supplemented with 2 mM L-glutamine, 100U/ml penicillin, 100µg/ml streptomycin and 10% FBS. Cells were harvested with 0.25% trypsin-EDTA and passaged once a week. Cells were maintained at 37 0 C under a humidified atmosphere with 5% CO 2.
Cytokine array and specific ELISA analysis.
The comparative presence of a 120 distinct cytokines and growth factors in human liver and kidney cyst fluids was evaluated by cytokine array analysis, as described by the manufacturer (Transignal Mouse Cytokine Antibody Arrays, RayBio, Redwood City, CA). Briefly, 1.5 ml human cyst fluid was incubated with Human Cytokine Antibody Arrays VI and VII supports, the captured factors labeled with a biotinylated antibody cocktail and detected by chemiluminescence using an UVP Photodocumentation System (Upland, CA). Densitometry of each signal was quantified using NIH Image software; values were normalized to internal controls present on each blot. The pattern of growth factors and cytokines that accumulated in mouse liver cyst fluids or were secreted in culture by pkd2(WS25/-) liver cyst epithelial cells was similarly evaluated using the mouse cytokine array 2 (RayBio; Redwood City, CA). Quantitation of human IL-8 and EGF and mouse KC was performed by ELISA, as described by the manufacturers (R&D biosystems; Minneapolis, MN and ElisaTech, Aurora, CO). Absorbance (405 nm) was measured using a microplate reader (Dynatech Laboratories; Chantilly, VA) and cytokine levels were correlated to internal standards included in each plate.
Cell proliferation assays.
The proliferation rates of the human cell culture models were measured by Alamar Blue assay, as described by the manufacturer (Biosource/Invitrogen; Carlsbad, were seeded onto the elastomer plates, allowed to attach overnight and then subjected to a stretching protocol. This protocol subjected cells to specific elongation over a 25 hour time period. This included 5%, 7.5%, 10%, 15% to 20% stretch with each increasing step taken after 5 hours. The cells experienced stretching at 20 cyles/minute. Previously shown to induce hypoxic gene response (15, 19) , cellular hypoxia was achieved by incubation of cells (1x10 5 /well in 12 well plates) in a 1% O 2 and 5% CO 2 environment for 8 hrs. Following the experimental period, the media was collected and IL-8 secretion was measured by ELISA (see above). Cell proliferation was measured by Alamar Blue assay (see above). IL-8 promoter activity was measured as described below.
IL-8 promoter activity assays.
Chimeric constructs of the 5' region of the IL-8 promoter
were previously ligated to a firefly luciferase reporter and used to evaluate IL-8 promoter activity (14). 
Statistical analysis.
All statistics were evaluated by GraphPad Instat (San Diego, CA) analysis software. In studies comparing two groups, the data was analyzed either by Student t-test of unpaired samples ( Figure 2 ; Table I ) or of paired samples ( Figure 6 ). p<0.05 was considered statistically significant. In studies comparing groups of three or more samples (Figures 4, 5, 7, 8 and 9) , the means were subjected to an analysis of variance. A Tukey multiple comparisons test was performed to identify which groups were significantly different (p<0.05). In the presentation of the analysis of variance, groups or bars without a shared letter are significantly different from each other.
RESULTS
Liver and kidney cyst fluids contain a distinct profile of cytokines and growth factors. Cytokine array analyses found the profile of cytokines and growth factors in ADPKD liver and kidney cyst fluids were markedly distinct ( Figure 1) . A densitometric analysis of all the factors detected in the individual arrays for liver (n=5) and kidney (n=6) cyst fluids is presented in Table 1 . These values were normalized to the internal control samples included in the arrays. The arrays showed some factors (e.g. angiogenin)
were present in both liver and kidney cyst fluids. Hepatocyte growth factor (HGF) was found sporadically, IL-8, ENA78 and GROα are each agonists for CXCR2 chemokine receptors, suggesting they may act in a coordinate fashion to impact cyst growth. Consequently, their concentrations in liver and kidney cyst fluids were measured directly by ELISA (Figure 2 ). The concentration of IL-8 was significantly higher in liver cyst fluids (4.13 ± 0.24 ng/ml; n=67; *p<0.05) than kidney cyst fluids (0.53 ± 0.07 ng/ml; n=30).
Similarly, the concentrations of ENA78 (liver: 1.18 ± 0.08 ng/ml, n=53; kidney: 0.05 ± 0.00 ng/ml, n=24) and GROα (liver: 2.10 ± 0.15 ng/ml, n=53; kidney: 0.03 ± 0.00 ng/ml, n=24) were higher in liver cyst fluids. As a comparative control, ELISA analyses of the same cyst fluid samples for EGF found the levels were below detection levels in both liver (0.00 ± 0.00 ng/ml) and kidney (0.01 ± 0.01 ng/ml) samples (data not shown). Importantly, CXCR2 is expressed at the apical domain of both normal and 'cystic' cholangiocytes (30) and is expressed in Mz-ChA1 cells (data not shown). The proliferative responses to IL-8 were measured qualitatively using PCNA expression ( Figure 5A ) and quantitatively using Alamar Blue reduction assay ( Figure 5B ). Elevated PCNA expression was observed in cells treated with 10 ng/ml or more of IL-8.
Similarly, Alamar Blue reduction showed a small but significant proliferative response to 1 ng/ml IL-8 (7 ± 3 % of 10% FBS response; n=4) and robust proliferative responses to IL-8 concentrations at or above 10 ng/ml IL-8 (10 ng/ml: 54 ± 4 % of 10% FBS response, n=4; 100 ng/ml IL-8: 73 ± 16% 10% FBS response; n=4). The proliferative response to 100 ng/ml IL-8 was completely inhibited in paired samples pre-treated with 50 nM SB225002 (n=4; data not shown).
The capacity of CXCR2 agonists within human liver cyst fluids to promote cell proliferation was measured in Mz-ChA1 cholangiocytes ( Figure 5C ). Treatment of Mz-ChA1 cells with 10% human liver cyst fluid induced a significant proliferative response (72 ± 4% of 10% FBS response; n=5). Inhibition of CXCR2 signaling with 50 nM SB225002 significantly reduced this proliferation response (32 ± 16% of 10% FBS response, n=4). Analysis of PCNA expression confirmed these observations with 10% human liver cyst fluid inducing a potent increase in the PCNA:actin ratio while normal human bile, a negative control, failed to induce cell proliferation (data not shown). As with the endothelial cells, the incomplete inhibition of proliferation by SB225002 suggests that other factors present within the liver cyst fluids also contribute to the proliferative response by these cells. Treatment with 10% kidney cyst fluid also induced Mz-ChA1 cell proliferation (60 ± 14% of FBS response, n=6). This proliferative response, however, was not inhibited by pre-treatment with SB225002 (59 ± 4% of 10% FBS response, n=4).
Hypoxia and cell stretch stimulates IL-8 synthesis by cyst epithelia. The expression of most cytokines and growth factors is moderated by external cues or 'stresses' placed on the cells. Evidence indicates that the ADPKD liver cyst epithelium is subjected to cell stretching (11, 12) and hypoxia (30) . In other cell types, cell stretching and hypoxia are potent inducers of IL-8 expression (19, 26) .
Consequently, the effect of cell stretching and hypoxia on IL-8 secretion by liver cyst epithelial cells was modeled by subjecting Mz-ChA1 cells to stretching or hypoxia ( Figure 6 ). Cell stretching induced an increase inIL-8 secretion (Basal: 0.91 ± 0.07 ng/ml1; Stretch: 1.56 ± 0.14 ng/ml; n=5). Similarly, hypoxia induced a significant increase in IL-8 release (Basal: 0.54 ± 0.13 ng/ml; Hypoxia: 0.89 ± 0.22 ng/ml; n=5).
While other stressors may also moderate IL-8 expression, these observations demonstrate that both hypoxia and cell stretching increase IL-8 synthesis and release.
Stress-responsive elements regulating IL-8 transcription.
The promoter has the AP-1 site deleted and the -50/+44 promoter has all three sites deleted. With the full length IL-8 promoter, the basal promoter activity (100%; n=8) was doubled in cells exposed to either cell stretching (220 ± 28%; n=8; Figure 7B ) or hypoxia (217 ± 24%; n=6; Figure 7C ). In the cell stretch study, the -272/+44 promoter had a diminished basal promoter activity (49 ± 7%; n=8) and failed to show a robust increase in promoter activity under stretched conditions (75 ± 18%; n=8; Figure 7B ). The -272/+44 construct in the hypoxia study retained its basal activity (83 ± 19; n=6; Figure 7C ) but showed no significant increase in activity under hypoxic conditions (124 ± 20%; n=6; Figure 7C ). Both the basal and stretch-induced promoter activities in the -98/+44 and -50/+44 truncation mutants were essentially abolished. In the hypoxia studies, the -98/+44 and -50/+44 promoter truncation mutants also presented minimal basal activities and no increase in promoter activities in response to hypoxia. PKD2 mutations. Further, ADPKD is considered a molecular recessive disease that arises from a germline mutation in one copy of the gene and a somatic mutation that later inactivates the second PKD allele. The rate, timing and intragenic site of the somatic mutation can impact cystogenesis (18, 34) .
Despite different rates of cystogenesis in individuals with PKD1 versus PKD2 mutations, the rates of cyst growth in these individuals are similar (9, 17) . This suggests that while cystogenesis is largely determined by the primary mutation but cyst growth is likely moderated by extra-genetic factors.
Significant intra-familial variability in disease severity also indicates that extra-genetic factors influence the presentation of the disease (31) . Some of the extra-genetic factors that modify disease severity have begun to be identified by genetic linkage analyses (13) . Discovering and defining the extra-genetic factors responsible for driving cyst growth is specifically important for liver cyst growth since it is the total volume (i.e. cyst growth) and not the number of liver cysts (i.e cystogenesis) that dictates the clinical presentation of ADPKD liver cyst disease.
Growth factor and cytokine profiles in liver and kidney cyst fluids are distinct. Cytokines and growth factors secreted by the cyst lining epithelial cells have long been predicted to promote cyst growth. Various pro-growth factors, including IL-1, IL-2, TNF-α, and EGF, have been reported to accumulate in kidney cyst fluids (16, 29, 40) . Factors such as IL-8, ENA78, IL-6 and VEGF, have been discovered more recently in ADPKD liver cyst fluids (30) . It remained unclear, however, if the cytokine/growth factor profile was largely determined by changes that occurred within all epithelial cells in which PKD1 or PKD2 was mutated or if the profile was largely independent of the primary mutation and dictated by the individual epithelial cell type forming the cyst. Paired cytokine array analyses and ELISA studies documented that, despite some overlap, the profiles were distinct and several factors were specific either to the liver or kidney cyst fluids. (Figure 1 ; Table 1 ). De-identification of the samples did not allow demographic differences in the liver and kidney cyst fluid donors to be evaluated. However, with liver cyst disease being far more prevalent in women than men and, conversely, kidney cyst disease is more prevalent in men than women, differences in the sex of the donors might influence the differences in the factors found in the liver and kidney cyst fluids. Regardless, the distinct cytokine and growth factor profiles indicate distinct mechanisms likely regulate the development and growth of the liver and kidney cysts and highlight the need to specifically study the molecular mechanisms underlying ADPKD liver cyst formation and growth.
CXCR2 agonists are concentrated in liver cyst fluids.
A striking difference between the liver and kidney cyst fluids was the higher concentrations of CXCR2 agonists, including IL-8, GROα and ENA78, in the liver cyst fluids (Figures 1 and 2 ). All three factors were present at levels near or above their dissociation constant for CXCR2 binding (24, 27) . Studied in the greatest detail, IL-8 is a potent proinflammatory chemokine, induces angiogenesis, promotes tumor invasion and metastasis and stimulates epithelial cell proliferation (3, 7, 22, 23, 33, 43) . In epithelial cell models, IL-8 has been shown to contribute to the induction of transepithelial migration of neutrophils (8) . Preliminary studies in liver cysts have not consistently found evidence of neutrophil infiltration into liver cyst fluids (data not shown) but additional studies are required to assess if CXCR2 agonists induce neutrophil migration or an inflammatory response into the liver cyst wall.
The secretion of IL-8 across both the apical and basolateral membranes, as seen in Figure 3 Evidence suggests that human 'cystic' cholangiocytes in liver cyst walls experience both stretching and hypoxia.
Cell stretching would be predicted to occur when fluid is secreted into the enclosed lumen of the liver cysts or the diaphragm presses down on the superficial liver cysts. In vitro studies using 
